4/26/2013

The global pharmaceutical market is poised to return to earnings growth this year as the patent cliff eases, according to a report from Moody's. Merger and acquisition deals will likely increase, but transactions will be in the small to midsize range. In the U.S., the regulatory pathway for biosimilars will get clearer, with potential regulatory applications this year, according to the report.

Full Story:
PharmaTimes (U.K.)

Related Summaries